- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07937982
Protocol CAUSE-05 RHINO (RHINO)
Respiratory Health & Infant Nasal 'Omics (RHINO) (CAUSE-05)
CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is an observational, multicenter study designed to assess developmental changes in in vivo and in cultured neonatal nasal epithelial cells. The study will enroll pregnant females in their third trimester of pregnancy as well as their infants upon delivery. Approximately 60 mother-infant pairs will be observed from birth to age 4 months to describe early-life developmental patterns of nasal cell gene expression, including genes related to type-II (T2) inflammation, immune response, and epithelial barrier function.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: James E Gern, MD
- Telefonnummer: 608-263-6201
- E-post: gern@medicine.wisc.edu
Studieorter
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Huvudutredare:
- Rajesh Kumar, MD
-
Kontakt:
- Sarah Godley
- Telefonnummer: 312-227-6454
- E-post: sgodley@luriechildrens.org
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University at St. Louis
-
Kontakt:
- Gina Simpson
- Telefonnummer: 314-362-9139
- E-post: simpsong@wustl.edu
-
Huvudutredare:
- Katherine Rivera-Spoljaric, MD
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
Huvudutredare:
- Neeru Hershey, MD
-
Kontakt:
- Molly Brausch-Bradner
- Telefonnummer: 513-803-0028
- E-post: molly.brausch-bradner@cchmc.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Pregnant maternal participants from the pre-selected recruitment census tracts designated by the CAUSE program, aged 18 years or older, with a gestational age greater than or equal to 28 weeks, in addition to one offspring of each maternal participant.
Beskrivning
Inclusion Criteria:
-
Able to understand and provide informed consent
-
Age 18 years or older
-
Currently pregnant, with:
- Gestational age ≥ 28 weeks as confirmed by participant self-report
- Intent to deliver at a participating clinical site labor and delivery (L&D) center
-
Agrees to enroll infant into the study at birth
-
In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
-
Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or comply with study protocol
- Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
- Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
- Pregnancy conceived via donor oocyte (egg donation)
- Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
- Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
- Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:
- Delivery before 36 weeks gestation
- Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Pregnant females 18 years and older and their infants upon delivery
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Gene expression of nasal swab RNA samples
Tidsram: 4 months
|
Gene expression will be measured by whole transcriptome RNA sequencing |
4 months
|
Samarbetspartners och utredare
Utredare
- Studiestol: James E Gern, MD, University of Wisconsin, Madison
- Studiestol: Jo L Wilson, MD, University of Wisconsin, Madison
- Studierektor: Daniel Jackson, MD, University of Wisconsin, Madison
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DAIT CAUSE-05
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Immunonology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Tidsram för IPD-delning
On average, within 24 months after database lock for the trial.
Kriterier för IPD Sharing Access
Open access
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .